KR20230066019A - 다가 sting 활성화 조성물 및 이의 용도 - Google Patents

다가 sting 활성화 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20230066019A
KR20230066019A KR1020237010998A KR20237010998A KR20230066019A KR 20230066019 A KR20230066019 A KR 20230066019A KR 1020237010998 A KR1020237010998 A KR 1020237010998A KR 20237010998 A KR20237010998 A KR 20237010998A KR 20230066019 A KR20230066019 A KR 20230066019A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
sting
pc7a
cancer
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010998A
Other languages
English (en)
Korean (ko)
Inventor
진밍 가오
수신 리
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20230066019A publication Critical patent/KR20230066019A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237010998A 2020-09-08 2021-09-08 다가 sting 활성화 조성물 및 이의 용도 Pending KR20230066019A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063075560P 2020-09-08 2020-09-08
US63/075,560 2020-09-08
PCT/US2021/049365 WO2022055929A1 (en) 2020-09-08 2021-09-08 Polyvalent sting activating compositions and uses thereof

Publications (1)

Publication Number Publication Date
KR20230066019A true KR20230066019A (ko) 2023-05-12

Family

ID=80469374

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010998A Pending KR20230066019A (ko) 2020-09-08 2021-09-08 다가 sting 활성화 조성물 및 이의 용도

Country Status (11)

Country Link
US (1) US12036319B2 (https=)
EP (1) EP4210707A4 (https=)
JP (1) JP2023546316A (https=)
KR (1) KR20230066019A (https=)
CN (1) CN116490193A (https=)
AU (1) AU2021340623A1 (https=)
BR (1) BR112023004271A2 (https=)
CA (1) CA3191593A1 (https=)
IL (1) IL301190A (https=)
MX (1) MX2023002797A (https=)
WO (1) WO2022055929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805309A (zh) * 2022-06-07 2022-07-29 中国药科大学 苯并杂环类化合物及其制备方法、药物组合物和应用
CN117599199B (zh) * 2023-11-20 2025-03-04 北京大学 用于靶蛋白水解的聚合物及其制备方法和用途
CN120242033B (zh) * 2025-06-03 2025-08-22 合肥市第一人民医院 一种纳米组装体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
CA3016457A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
EP3691640A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Methods for administering sting agonists
WO2019161171A1 (en) 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
US11096899B2 (en) * 2018-09-07 2021-08-24 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment
JP7676331B2 (ja) * 2019-06-22 2025-05-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生分解性超ｐＨ感受性ポリマー

Also Published As

Publication number Publication date
CA3191593A1 (en) 2022-03-17
CN116490193A (zh) 2023-07-25
IL301190A (en) 2023-05-01
JP2023546316A (ja) 2023-11-02
BR112023004271A2 (pt) 2023-04-04
AU2021340623A1 (en) 2023-04-13
WO2022055929A1 (en) 2022-03-17
EP4210707A4 (en) 2024-10-16
MX2023002797A (es) 2023-05-04
US20220071903A1 (en) 2022-03-10
EP4210707A1 (en) 2023-07-19
US12036319B2 (en) 2024-07-16

Similar Documents

Publication Publication Date Title
KR20230066019A (ko) 다가 sting 활성화 조성물 및 이의 용도
CN109963564A (zh) 用于核酸递送的解体型细胞穿透性复合物
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
JP2010526091A5 (https=)
WO2017044803A1 (en) Expression vector delivery system and use thereof for inducing an immune response
JP7811545B2 (ja) ｐＨ応答性ブロックコポリマー組成物、ミセル、及び使用の方法
US20240277854A1 (en) Immolative cell-penetrating complexes for nucleic acid delivery to the lung
JP2020517599A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
KR20230097142A (ko) 치료용 pH 반응성 조성물
AU2020335917B2 (en) Conjugated inhibitors of DNA damage response
US11786464B2 (en) PH responsive block copolymer compositions and micelles that inhibit MCT 1 and related proteins
US20220000887A1 (en) Repurposed antibiotics for non-nuclear genotoxic chemotherapy and pharmaceutical composition for anti-cancer containing the same
JP6580030B2 (ja) カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途
HK40094751A (zh) 多价sting激活组合物及其用途
Verschuere et al. Enhancing anti-tumor immunity through intratumoral combination therapy with amphiphilic conjugates of oxaliplatin and imidazoquinoline TLR7/8 agonist
HK40092555A (zh) 治疗性ph响应性组合物
HK40077764B (zh) Ph响应性嵌段共聚物组合物、胶束和使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230330

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240903

Comment text: Request for Examination of Application